BIOKIN PHARMACEUTICAL(SH:688506) Shang Hai Zheng Quan Bao·2026-01-16 20:39Core Viewpoint - The major shareholder OAP III (HK) Limited plans to reduce its stake in Sichuan Baili Tianheng Pharmaceutical Co., Ltd. due to personal funding needs, intending to sell up to 4,128,738 shares, which represents no more than 1.00% of the company's total share capital [1][2]. Shareholder Information - As of the announcement date, OAP III (HK) Limited holds 28,527,171 shares, accounting for 6.91% of the total share capital of the company [1]. - The shares to be sold were acquired prior to the company's initial public offering and have been released from restrictions as of January 8, 2024 [1]. Reduction Plan Details - The reduction will occur through centralized bidding within three months after the announcement, starting fifteen trading days from the disclosure date [1]. - The selling price will be determined based on the market price at the time of the sale, and it will not be lower than the initial public offering price [2]. Compliance and Commitments - OAP III (HK) Limited has no other arrangements regarding the reduction and has made prior commitments regarding its shareholding, including not transferring shares within 12 months of the company's listing [3][4]. - The company has agreed to compensate for any losses incurred due to violations of these commitments [4][5]. Regulatory Compliance - The planned reduction complies with relevant laws and regulations, including the Shanghai Stock Exchange's guidelines for shareholder reductions [8].